Lung Cancer Surgery Market By Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Lung Cancer Surgery Market
Lung Cancer Surgery Market: By Type (Thoracotomy, Minimally Invasive Procedures), By End-User (Hospitals, Adult Lung Cancer Surgery Centers, Ambulatory Surgical Centers) & By Region-Forecast (2016-2021)
Report Code : HCR 0316
Updated Date: 25 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
1. Lung Cancer Surgery Market – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Lung Cancer Surgery Market– Market Forces
   4.1. Drivers
      4.1.1. Favorable reimbursement scenario in the developed countries favors the market for lung cancer surgery
      4.1.2.  Innovations in diagnosis and alternate treatment therapies hinder the surgery market for lung cancer
   4.2. Restraints
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Lung Cancer Surgery Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Lung Cancer Surgery Market, By Type
   6.1. Thoracotomy
   6.2. Minimally Invasive Procedures
      6.2.1. Video-Assisted Thoracoscopic Surgery (Vats)
      6.2.2. Robotic Surgery
   6.3. Others
7. Lung Cancer Surgery Market, By End-User
   7.1. Hospitals
   7.2. Adult Lung Cancer Surgery Centers
   7.3. Ambulatory Surgical Centers
8. Lung Cancer Surgery Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Lung Cancer Surgery – Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   10.1. Siemens Healthcare
   10.2. Richard Wolf Gmbh
   10.3. Olympus Cor
   10.4. Neomend Inc.
   10.5. Ethicon Endo-Surgery Inc.
   10.6. Bsd Medical Corp
   10.7. Accuray Inc.
   10.8. Trokamed Gmbh
   10.9. Karl Storz Gmbh & Co. Kg
   10.10. Teleflex Inc.
   10.11. Scanlan International Inc.
   10.12. Intuitive Surgical Inc.
   10.13. Dimeda Surgical Instruments
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Lung cancer is the most common type of cancer prevailing across the globe. According to WHO, lung cancer is expected to be more prominent in the underdeveloped world due to an increase in the use of tobacco products; tobacco is the primary cause of around 80% of all lung cancers. According to WHO,  lung cancer cases in developing economies is expected to reach 2,530,820 by 2025. Globally increasing awareness about cancers and about available treatments coupled with favourable reimbursement scenario in the developed countries favors the market for lung cancer surgery. These two factors are expected to be the key growth drivers for the lung cancer surgery market during the period of study.

 Lung Cancer Surgery Market

Geographically North America dominated global lung cancer surgery market driven by best in the class healthcare infrastructure, advanced facilities and awareness and higher spending by the citizens towards healthcare expenditure. North America was followed by Europe and Asia-Pacific as second and third largest market  for lung cancer surgery market. Asia Pacific is projected to have fastest growth, owing to rapidly increasing healthcare infrastructure, increased spending, government initiatives and increasing awareness amongst population, and growing medical tourism industry in developing nations such as China, and India in this region.

This report identifies the global lung cancer surgery market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global lung cancer surgery market.

This report segments global lung cancer surgery market on the basis of by type, end-user and regional market as follows:
  • Lung Cancer Surgery Market, By Type: Thoracotomy, Minimally Invasive Procedures (Video-Assisted Thoracoscopic Surgery (Vats), Robotic Surgery)
  • Lung Cancer Surgery Market, End-User: Hospitals, Adult Lung Cancer Surgery Centers, Ambulatory Surgical Centers
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the lung cancer surgery market. Some of the major companies’ profiles in detail are as follows:
  • Siemens Healthcare
  • Richard Wolf Gmbh
  • Olympus Cor
  • Neomend Inc.
  • Ethicon Endo-Surgery Inc.
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports